AbbVie posted strong Q1 2025 results and raised guidance, but early-stage obesity pipeline and fair valuation limit upside.

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

RTX carries a strong balance sheet with a BBB+ credit rating from S&P. This is supported by $5.2 billion in cash on hand, and ...

After a 2024 in which AbbVie’s Skyrizi boasted the highest TV drug ad spending outlay on seven of our monthly roundups—and took second place in four more—the immunology med has seen that ...

AbbVie’s Skyrizi took home the top spot for most pharma brand ad impressions in April 2025, according to data released by iSpot.tv on Wednesday afternoon. The psoriasis treatment garnered an ...

AbbVie’s Allergan aesthetics unit is tightening up its workforce with 202 layoffs. | The layoffs at Allergan's Irvine, ...

AbbVie’s Skyrizi has been approved by the FDA as a treatment for ulcerative colitis, making it the first IL-23 inhibitor indicated for both major types of inflammatory bowel disease (IBD ...

Berkshire Hathaway, AbbVie and Intuitive Surgical beat estimates as analysts highlight growth drivers, headwinds and ...

Better-than-expected sales of some of its new products, including Skyrizi and Rinvoq, helped AbbVie handle a sharp decline in sales of former cash-cow product Humira in the last quarter of 2023.

AbbVie (NYSE:ABBV) experienced a 6.8% share price increase over the past month, coinciding with several significant corporate events. The company announced a collaboration with ADARx Pharmaceuticals ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.